ストックスクリーナーアプリを入手
3.65
3.69%
0.13
アフターアワーズ：
3.50
-0.15
-4.11%
前日終値:
$3.52
開ける：
$3.42
24時間の取引高:
341.23K
Relative Volume:
2.56
時価総額：
$215.78M
収益：
$34.16M
当期純損益:
$-98.43M
株価収益率:
-1.5598
EPS:
-2.34
ネットキャッシュフロー:
$-119.33M
1週間 パフォーマンス:
-13.51%
1か月 パフォーマンス:
-24.74%
6か月 パフォーマンス:
-60.79%
1年 パフォーマンス:
-45.60%
1日の値動き範囲:
$3.29
$3.75
1週間の範囲:
$3.29
$4.20
52週間の値動き範囲:
$3.29
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
名前
Foghorn Therapeutics Inc
セクター
電話
617-586-3100
住所
500 TECHNOLOGY SQUARE, CAMBRIDGE
FHTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
3.65 | 215.78M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-30 | 開始されました | B. Riley Securities | Buy |
| 2024-09-03 | 開始されました | Jefferies | Buy |
| 2024-08-19 | 開始されました | Evercore ISI | Outperform |
| 2023-03-28 | 開始されました | BofA Securities | Buy |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-22 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-17 | 開始されました | Cowen | Outperform |
| 2020-11-17 | 開始されました | Goldman | Buy |
| 2020-11-17 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-17 | 開始されました | Wedbush | Outperform |
すべてを表示
Foghorn Therapeutics Inc (FHTX) 最新ニュース
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Trend Tracker for (FHTX) - news.stocktradersdaily.com
Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients (NASDAQ:FHTX) - Seeking Alpha
Foghorn Therapeutics Announces New Preclinical Data for - GlobeNewswire
Breakthrough Cancer Drug FHD-909 Reveals Powerful Combination Potential Against Lung Cancer - Stock Titan
Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Target Price at $13.17 - Defense World
2,029,383 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Bought by Raymond James Financial Inc. - Defense World
Foghorn Therapeutics adjusts ATM offering to $100M By Investing.com - Investing.com Australia
Foghorn Therapeutics adjusts ATM offering to $100M - Investing.com
What is B. Riley’s Forecast for FHTX Q1 Earnings? - Defense World
Foghorn Therapeutics Reports Progress and Financial Stability - TipRanks
Rhumbline Advisers Purchases 3,049 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics’ (FHTX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Promising Advancements and Strategic Collaborations Position Foghorn Therapeutics as a Strong Buy - TipRanks
Promising Potential of Foghorn Therapeutics’ FHD-909 Drives Buy Rating Amid Strategic Advances - TipRanks
Foghorn Therapeutics Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Foghorn Therapeutics 2024 Net Loss Narrows, Revenue Declines -- Shares Slipping Late - Marketscreener.com
Foghorn Therapeutics Continues Enrollment in Phase 1 Trial of First-in-Class SMARCA2 Inhibitor FHD-909 for NSCLC and Reports Strong Financial Outlook - Nasdaq
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook - GlobeNewswire
Can Foghorn's $243M War Chest Transform Cancer Treatment? Key Pipeline Updates - StockTitan
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know - MSN
Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses - Yahoo Canada Finance
Foghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on Thursday - Defense World
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Can Foghorn's Gene Traffic Control Platform Impress Investors at Upcoming Healthcare Conferences? - StockTitan
How To Trade (FHTX) - Stock Traders Daily
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 29% But Growth Is Lacking - Simply Wall St
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health – Company Announcement - Financial Times
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
FHTX Stock Price and Chart — NASDAQ:FHTX - TradingView
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock? - MSN
Layoff Tracker: Q32, Inventiva, Third Harmonic Cut Staff - BioSpace
Eagle financial services executive buys $3,200 in stock - MSN
CENX’s Stock Woes: Up 59.32% in 6 Months, Up 59.32% in Just 5 Days - The InvestChronicle
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Harmony Gold Mining Co Ltd ADR (HMY) Stock: A Study of the Market Performance - The News Heater
Foghorn Therapeutics Inc (FHTX) Shares Up Despite Recent Market Volatility - The News Heater
Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks - Markets Insider
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now - Yahoo Finance
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 - Yahoo Finance
What is B. Riley's Forecast for FHTX FY2024 Earnings? - MarketBeat
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference - Yahoo Finance
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Yahoo Finance
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Delivered A Weaker ROE Than Its Industry - Yahoo Finance
Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Upgraded by B. Riley - MarketBeat
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today - Yahoo Finance
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Foghorn Therapeutics Inc (FHTX) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):